4,782
Views
6
CrossRef citations to date
0
Altmetric
Articles

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis

ORCID Icon, , , , ORCID Icon, , , , ORCID Icon, & ORCID Icon show all
Pages 2085-2093 | Received 23 Mar 2021, Accepted 06 Apr 2021, Published online: 05 May 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Andreas Schneider, Reto Jost, Christoph Jordi & Jakob Lange. (2023) Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions. Expert Opinion on Drug Delivery 20:6, pages 815-830.
Read now

Articles from other publishers (4)

Jacopo Fanizza, Ferdinando D’Amico, Francesca Lusetti, Ernesto Fasulo, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese & Gionata Fiorino. (2023) The Role of IL-23 Inhibitors in Crohn’s Disease. Journal of Clinical Medicine 13:1, pages 224.
Crossref
April W. Armstrong, Richard B. Warren, Yichen Zhong, Joe Zhuo, Allie Cichewicz, Ananth Kadambi, Daniela Junqueira, Tracy Westley, Renata Kisa, Carolin Daamen & Matthias Augustin. (2023) Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy 13:11, pages 2839-2857.
Crossref
Emilie Sbidian, Anna Chaimani, Robin Guelimi, Ignacio Garcia-Doval, Camille Hua, Carolyn Hughes, Luigi Naldi, Maria Kinberger, Sivem Afach & Laurence Le Cleach. (2023) Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Roy M. Fleischmann, Amy E. Bock, Wuyan Zhang, Charles M. Godfrey, Ivana Vranic, Carol Cronenberger & Eva Dokoupilová. (2022) Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis. Rheumatology and Therapy 9:3, pages 839-850.
Crossref